Clinical trials: Plasma Cell Tumor
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
RATIONALE: Questionnaires that measure coping may improve the ability to plan supportive care for patients undergoing donor bone marrow transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281814
- Testing
- psychosocial assessment and care
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- The Cleveland Clinic
Myeloma, Multiple, Paraproteinemias
Comprehensive Frailty Assessment
The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health.
- Conditions
- Myeloma, Multiple, Paraproteinemias, Hematologic Neoplasms
- Trial name
- NCT02033928
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Plasma Cell Myeloma
Daratumumab in Treating Patients With Multiple Myeloma
This phase II trial studies the side effects and how well daratumumab works in treating patients with multiple myeloma when the infusion is accelerated.
- Trial name
- NCT02944565
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439344
- Testing
- Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
This phase II trial studies the effect of isatuximab, carfilzomib, and pomalidomide in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory).
- Trial name
- NCT04850599
- Testing
- Carfilzomib, Isatuximab, Pomalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Multiple Myeloma
Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma
This study involves receiving blinatumomab after high-dose melphalan and ASCT for multiple myeloma. The main purpose of this study is to: - To determine whether blinatumomab is safe and feasible to administer after ASCT in…
- Trial name
- NCT03173430
- Testing
- Blinatumomab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma, Amyloidosis
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among…
- Conditions
- Multiple Myeloma, Amyloidosis, Plasma Cell Leukemia
- Trial name
- CARE-Heme (NCT05556928)
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- University of Alabama at Birmingham
Renal Failure, Multiple Myeloma
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
Primary: To validate the initial dosing recommendations for newly diagnosed MM (Mutiple Myeloma) patients with various degrees of renal failure using pharmacokinetic studies Secondary: To evaluate the safety of lenalidomide and…
- Trial name
- NCT01270932
- Testing
- Lenalidomide and Dexamethasone
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University Health Network, Toronto
Newly Diagnosed, High Risk
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
The goal of this study is to evaluate sustained MRD negativity for one year in DKRD induction \& consolidation therapy +/- ASCT in newly diagnosed high-risk multiple myeloma patients.
- Conditions
- Newly Diagnosed, High Risk, MRD, Multiple Myeloma
- Trial name
- NCT06409702
- Testing
- Carfilzomib, Daratumumab, Lenalidomide
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT00963872
- Testing
- cyclophosphamide, fludarabine phosphate, Total body irradiation
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Exercise in Patients With Multiple Myeloma
The overall aim is to examine whether early initiated, individualized exercise training in patients newly diagnosed with multiple myeloma, irrespective of age and current performance status, will be beneficial for the…
- Trial name
- EMMY (NCT02439112)
- Testing
- Exercise
- Where
- Denmark
- Volunteers
- 102 people
- Sponsor
- Zealand University Hospital
Lymphoma, Leukemia
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma
- Trial name
- NCT00621244
- Testing
- LBH589
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
This phase II trial studies the effectiveness of melphalan, peripheral stem cell transplantation, and interleukin-2 followed by interferon alfa in treating patients who have advanced multiple myeloma (MM).
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00006244
- Testing
- melphalan, recombinant interferon alfa, aldesleukin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Smoldering Myeloma
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors find better ways to ways to treat the cancer.
- Conditions
- Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT00919139
- Testing
- biologic sample preservation procedure
- Where
- 207 sites in United States
- Volunteers
- 190 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma, Multiple Myeloma in Relapse
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
This is a phase 1/2, open label, single-center study designed to assess the safety and preliminary clinical activity of different belantamab mafodotin doses in combination with daratumumab, pomalidomide, and dexamethasone (DPd)…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal
- Trial name
- NCT05581875
- Testing
- Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide
- Volunteers
- 48 people
- Sponsor
- Hellenic Society of Hematology
Lymphoma, Myeloma
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online.
- Conditions
- Lymphoma, Myeloma, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
- Trial name
- NCT07390071
- Testing
- Home Automated Telemanagement (HAT) Patient Unit
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Utah
Plasma Cell Neoplasms
In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
This study aims to assess the safety profile of in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy in patients with relapsed or refractory plasma cell neoplasms.
- Trial name
- NCT07586709
- Testing
- In vivo BCMA/GPRC5D Tandem Dual CAR-T cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Liping Dou
Amyloidosis
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .
- Trial name
- ALANIS (NCT07224672)
- Testing
- Belantamab mafodotin, Cyclophosphamide, Bortezomib
- Where
- 5 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Recurrent Plasma Cell Myeloma
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant.
- Trial name
- NCT03622775
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms
Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases
- Trial name
- NCT02804100
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wenzhou Medical University